What podcasters are saying about GLP-1s & obesity drugs

Summary

In the past 30 days, 6 speakers on 5 finance podcasts discussed GLP-1s & obesity drugs in 7 views. Chorus has followed GLP-1s & obesity drugs since October 1, 2026.

Who talks about it most

• Dana Telsey · 2
• Will Ahmed · 1
• Mark Cuban · 1
• Craig Fuller · 1
• Lance Roberts · 1
• Jonathan Boyar · 1

The latest views

Newest first. Every quote is checked against the episode's transcript.

• Will Ahmed · WHOOP

  GLP-1 users lose muscle as well as fat, so they need activity, strength training and protein to avoid frailty.

  Ahmed says that typically about 50% of the weight a GLP-1 user loses is fat and 50% is muscle, which can leave people frail even after a large weight loss. He argues that WHOOP knowing a member is on a GLP-1 lets it push activity and some strength training, even bodyweight work, to preserve muscle. He points to a proper diet with protein and anecdotal success with creatine as important. This is why WHOOP built a GLP-1 tracker that sets protein, strength and step targets.

  “is that typically speaking about 50% of the weight that someone loses is fat and 50% is muscle.”at 33:07

  All-In Podcast: WHOOP CEO, Will Ahmed: 50B Hours of Health Data, a 4 Million Member Data Moat, & the FDA Fight · October 29, 2026

• Mark Cuban · Cost Plus Drugs

  Food makers are unprepared for GLP-1 disruption; AI can design cheaper GLP-1-friendly rivals in minutes.

  Cuban recounts a meeting with a consumer food company head who was discussing acquisitions because of GLP-1 drugs. Cuban asked ChatGPT to design a cheaper, GLP-1-friendly competitor to the company's top cookie, complete with a full bill of materials and sources. It produced the answer in about three minutes, and the executive realized he had not considered the threat. Cuban uses the example to show that many companies do not understand how AI can be used against their products.

  “let's take your number one product, your cookie, and I'm going to ask ChatGPT to create a competitor that is more GLP-one friendly and will be priced lower... in about three minutes we got back to it, he was like, Oh, shit.”at 30:03

  a16z Podcast: Mark Cuban’s Plan to Make Healthcare Affordable · October 28, 2026

• Craig Fuller · FreightWaves

  GLP-1 drugs are a much bigger drag on food consumption than most people realize.

  Craig's firm talks to companies in reverse logistics and returns processing, which show food products sitting on shelves longer, concentrated in food categories. He describes his own three years on a GLP-1, where appetite disappears, and argues that across the 10+ million users this shows up in the freight data.

  “And then I think the GLP one factor is a much bigger deal than most people believe it is.”at 10:22

  Thoughtful Money: "No Signs Of The A.I. Party Slowing Down" | Craig Fuller · October 27, 2026

• Lance Roberts · RIA Advisors

  GLP-1s cut food volume but won't cure obesity unless people also change diet and exercise habits.

  Lance says GLP-1s work mainly by suppressing appetite, so people eat less and food volume falls. Many people who lose weight on the drug do not change their habits, and the weight returns quickly when they stop taking it. He argues the medical community must teach people to fix diet and exercise alongside the drug. Otherwise the drug is a treatment, not a cure. The food-volume point connects to Craig's earlier point that consumer shipments are weakening.

  “The GLP-one isn't a cure all be all end all solution. It's not gonna cure obesity if we don't change the way we eat as a culture.”at 46:35

  Thoughtful Money: Compressed Market Poised To Break Hard: The Key Question Is Which Way? | Lance Roberts · October 24, 2026

• Dana Telsey · Telsey Advisory Group

  GLP-1 users are driving spending across food, apparel, beauty and fitness, making GLP-1s a consumer accelerant.

  About 11% of US adults now use GLP-1s, more women than men, and use is still rising given the health benefits shown. Users are changing spending across the lifestyle spectrum: protein and food, new clothing and size changes, skin care and moisturizers, gym workouts, dinners out and beauty treatments. Shoppers also buy gifts for people on the drugs, so GLP-1s are, in her view, a consumer accelerant for spending.

  “GLP ones are definitely a consumer accelerant in terms of spending.”at 2:08

  Bloomberg Talks: Telsey Advisory Group Founder Dana Telsey Talks GLP-1s · October 20, 2026

• Dana Telsey · Telsey Advisory Group

  Oral GLP-1 dosing and falling prices should widen the user base beyond people who would inject.

  The shift from injections to oral dosage should open the market to many people who did not want to inject. Costs are also falling while health benefits increase, which she sees as a further reason adoption will keep growing.

  “I would think that would open up the market to a whole ton of people that maybe did not wanna inject. ... It's getting cheaper. The cost of GLP ones is coming down.”at 2:23

  Bloomberg Talks: Telsey Advisory Group Founder Dana Telsey Talks GLP-1s · October 20, 2026

• Jonathan Boyar · Boyar Value Group

  GLP-1 drugs are a factor for restaurants, but Americans will still eat burgers and fries.

  Boyar says GLP-1 drugs are a factor in restaurant demand, but restaurant companies are adjusting with smaller portions and different products. He is unsure how long people stay on the drugs, given their side effects. He expects people to eat somewhat less but says Americans will still eat hamburgers and fries. He treats GLP-1s as one part of a mix of pressures on restaurant stocks, alongside gas prices and a weak consumer, and not as the single main driver.

  “But people are still going to eat, maybe eat a little bit less. But I think Americans are still going to eat their hamburgers and fries.”at 13:03

  The Acquirers Podcast: Great Companies, Beaten-Down Stocks: Booking & Pool Corp with Jonathan Boyar · October 1, 2026